News

Spero Therapeutics Receives Grant from NIH for SPR720

Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis

CAMBRIDGE, Mass., May 4, 2017—Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today announced that it has received a grant from the National Institutes of Health (NIH) to conduct additional preclinical studies of SPR720, the Company’s novel oral bacterial gyrase inhibitor, for the treatment of tuberculosis (TB). The non-dilutive grant of $564,718 is part of the NIH’s Small Business Innovation Research (SBIR) program (Grant Number: 1R44AI131749-01).

As part of this research program, Spero will collaborate with the Central New York Research Corporation to assess the safety and efficacy of SPR720 in combination with rifampin and other existing standard-of-care drugs in preclinical models of both drug-susceptible TB and multidrug resistant (MDR) TB. The goal of the research is to assess novel combinations that could potentially shorten the duration of treatment and identify new drug combinations that would be effective against MDR TB.

“We are pleased with the progress we have made in characterizing the utility of SPR720 in non-tuberculous mycobacteria since acquiring the compound last year and we are excited to expand our research to TB,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero. “Our strategy is focused on discovering, developing and commercializing antibiotics in areas of unmet need. Like NTM, TB has high rates of mortality and current treatment options are becoming less effective as the rate of multidrug resistance continues to grow.”

Read full press release here

More News
9 Aug 2017
The United States Food and Drug Administration held a public workshop regarding scientific and clinical trial design considerations for development of new tuberculosis drug regimens. This public workshop was intended to provide information for and gain perspective pertaining to development efforts...
11 Apr 2017
Scientist at Rutgers University and their collaborators have published an article in Molecular Cell illustrating the three-dimensional structure of the drug target for the drug rifampicin. The abstract for the article is below. TITLE: Structural Basis of Mycobacterium tuberculosis Transcription and...
22 Mar 2017
March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive...